Find out what makes us such a unique institution and discover the vibrant student life that is at the heart of our community.
Learn more about our key research areas and our research objectives.
See how our research transforms people’s lives in our community, throughout the UK and around the world
Read our guidance for staff, students and applicants.
The latest results from a study have shown that an arthritis drug, baricitinib, reduced mortality in patients hospitalised with Covid-19
Jonathan Friedland works to develop and enhance the university strategy of pursuing excellent and ambitious research, both responding to major and emerging healthcare challenges and delivering significant societal impact. In addition, the Deputy Principal helps foster a culture of enterprise involving diverse partners, including St George’s University Hospitals NHS Foundation Trust.
Professor Jon Friedland is Deputy Principal (Research & Enterprise) at St George’s, University of London having been Hammersmith Campus Director and Head of Infectious Diseases and Immunity at Imperial College London.
His major research interests are in development of host mediated therapies targeting innate immune responses in tuberculosis and in migrant health. He has published over 235 peer reviewed papers, invited editorials and reviews, and edited 3 books.
Jon Friedland was awarded the Royal College of Physicians Weber-Parkes Prize Medal for research in tuberculosis in 2005. He was elected Fellow of the Academy of Medical Sciences in 2008. He was elected President of the British Infection Society (2007-09). He was made Fellow of the Royal College of Physician of Ireland (FRCPI) in 2010.
In 2017, he was awarded an inaugural Fellowship of the European Society of Clinical Microbiology and Infectious Diseases and in 2020, was elected to serve on the Society Executive Committee where he is Scientific Affairs Officer.
Jon Friedland is currently a Commissioner on the Commission for Human Medicines and Chair of the MHRA Expert Advisory Group on Infection. In 2020, he was appointed Chair of the Commission of Human Medicines Expert Working Group on Covid-19.
He has previously served on the Joint Committee on Vaccination and Immunisation (2005-13) where he was Chair of the Pneumococcal Vaccine Subgroup. He was also a member of The Chief Medical Officers National Expert Panel on New and Emerging Infections (2007-12). He has served on many grants committees including for the Medical Research Council (UK) and The Wellcome Trust.
Jon Friedland's research interests are currently in 2 major areas:
1) The innate inflammatory immune response to tuberculosis (TB). There is a particular focus on the enzymes (matrix metalloproteinases) driving tissue destruction in pulmonary and central nervous system tuberculosis. This research was initiated twenty years ago and current areas of particular focus are:
2) Migration and infection. This area started as a small interest in 1996 when funding was scarce and international interest was minimal but there is now a well-established research group co-led by Dr. Sally Hargreaves whose particular interest is in vaccination and migrants. Other current interests of the Migrant Research Group are:
Other areas of research interest in recent times include the immunopathology of neurocysticercosis, novel diagnostics for TB (particularly the MODS assay) and transmission of TB infection.
My research has always been the results of excellent teamwork involving many talented individuals. The team has continually evolved over the years and has included many outstanding postdocs, Clinical Research Fellows at all levels and PhD students.
I am also indebted to multiple collaborators and friends too numerous to list (some of whom were once members of the group); they now work across 5 continents. There is a particularly long-standing collaboration with Professor RH Gilman, Johns Hopkins University, Baltimore, USA and at Universidad Cayetano Heredia Peruana in Lima, Peru.
Current members of the Research Team are in alphabetical order:
Browser does not support script.